SIRT1 and fatty liver disease: The nicotine adenine dinucleotide (NAD(+)−dependent protein deacetylase activation of SIRT1 is positively associated with the protection of hepatocytes against palmitate-induced lipotoxicity [26], and is currently emerging as a potential therapeutic target for treating fatty liver disease [27,28].